Vitamin D Analog Paricalcitol Shows Promise in Pancreatic Cancer Trial by Reprogramming Tumor Microenvironment
Key Insights
A phase I clinical trial led by Dana-Farber Cancer Institute demonstrated that paricalcitol, an FDA-approved vitamin D analog, can safely be combined with standard chemotherapy in metastatic pancreatic cancer (search) patients.
The study validated preclinical findings from Salk Institute (search) by showing paricalcitol reduces fibroblast activation in tumor microenvironments and increases T cell infiltration.
Patients receiving paricalcitol showed improved chemotherapy response rates (42% vs 9% for placebo) and better progression-free survival at one year.
A small clinical trial has provided the first human evidence that a vitamin D analog can safely reprogram the protective microenvironment surrounding pancreatic tumors, potentially making this notoriously treatment-resistant cancer more vulnerable to therapy.
The phase I study, published May 25, 2026, in Nature Cancer, tested paricalcitol—an FDA-approved vitamin D analog currently used for kidney disease—in combination with standard chemotherapy for patients with previously untreated metastatic pancreatic cancer (search). The trial was led by researchers at Dana-Farber Cancer Institute, building on foundational discoveries from the Salk Institute (search) about vitamin D receptor (search) function in tumor biology.
Clinical Trial Design and Safety Results
The randomized trial enrolled 36 participants with metastatic pancreatic cancer (search) who were assigned to receive standard chemotherapy (gemcitabine plus nab-paclitaxel) combined with either placebo, intravenous paricalcitol, or oral paricalcitol. The primary objective was to assess safety rather than efficacy.
"Paricalcitol was safely administered with chemotherapy overall, although five of 12 participants receiving oral paricalcitol experienced elevated blood calcium, which was manageable through standard dosing reductions," the researchers reported.
The study's secondary goal involved analyzing molecular and cellular changes through paired patient biopsies collected at screening and after four to six weeks of treatment. Using advanced multiplex immunofluorescence and spatial transcriptomic methods, researchers found that paricalcitol reduced fibroblast activation within tumors while increasing infiltration of T cells—immune cells typically excluded from pancreatic tumors.
Promising Efficacy Signals
Although not designed to measure treatment effectiveness, the trial revealed encouraging differences in patient outcomes. Partial responses to treatment occurred in 42% of patients receiving paricalcitol (10 out of 24) compared to just 9% in the placebo group (one out of 12). Additionally, five patients who received paricalcitol remained progression-free at one year, while none in the placebo group achieved this milestone.
The researchers also discovered that vitamin D receptor (search) expression levels in tumors correlated with outcomes. Patients with high vitamin D receptor expression who received paricalcitol demonstrated better chemotherapy responses and the longest overall survival times.
Scientific Foundation and Mechanism
The clinical trial built upon decades of research by Ronald Evans, PhD, at the Salk Institute (search), who discovered the nuclear receptor superfamily that includes the vitamin D receptor (search). Evans' team previously demonstrated that vitamin D receptors regulate fibroblasts (search) in liver and pancreas tissue, and that synthetic vitamin D analogs could block liver fibrosis (search) and pancreatitis (search) in preclinical models.
"This study really takes a novel approach for cracking therapeutic resistance in pancreatic cancer (search)," said Evans, study co-author and professor at Salk Institute (search). "By using vitamin D analogs to engage the body's own natural system for dampening fibrotic and inflammatory responses, we can enable other therapies to do their job."
The research showed that fibroblasts (search)—cells forming connective tissue—create a protective shield around pancreatic tumors. In pancreatic cancer (search) models, vitamin D analogs reversed the activation of cancer-associated fibroblasts and promoted chemotherapy responses, providing one of the first examples of reprogramming the supportive microenvironment that protects pancreatic cancer cells.
Clinical Significance and Future Directions
Pancreatic cancer (search) remains among the most difficult cancers to treat, with standard chemotherapy providing limited benefit and poor outcomes largely attributed to the tumor microenvironment's contribution to therapy resistance. Pancreatic tumors are typically surrounded by dense, fibroblast-rich connective tissue that creates barriers to drug delivery and establishes an immunosuppressive environment.
The trial findings establish a foundation for larger clinical studies designed to evaluate how vitamin D analogs combined with chemotherapy or other cancer therapies impact survival outcomes. Future research will also investigate whether baseline vitamin D receptor (search) expression can serve as a reliable biomarker for predicting patient responses to combination therapies.
"This study is an important step forward for the use of a vitamin D analog as a stromal remodeling therapy that can overcome therapeutic resistance in pancreatic," said Kimberly Perez, MD, study co-leader at Dana-Farber. "It was built upon foundational basic research at the Salk Institute (search), validates those preclinical findings in patients, and provides a road map for future studies that could someday establish a new treatment standard."
The research represents a notable example of translating basic science discoveries into clinical applications, particularly significant given that approximately 13% of all FDA-approved drugs currently work by targeting nuclear receptors discovered by Evans' laboratory.